ArticleCost effectiveness and resource allocation : C/E2025
Cost-effectiveness of ceftolozane/tazobactam compared to meropenem in ventilator-associated pneumonia.
Jefferson Antonio Buendía et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.